Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a beta‑adrenergic blocking agent presented as an oral dosage form for oral administration. It selectively antagonizes β1‑adrenergic receptors, reducing heart rate and myocardial contractility while enhancing nitric‑oxide‑mediated vasodilation, thereby lowering elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across global markets.

Nebilet (nebivolol) is used to treat conditions within the cardiovascular disease pathway, primarily hypertension.

- Hypertension: lowers blood pressure and reduces cardiovascular risk in adult patients. - Heart failure: improves left‑ventricular function and alleviates symptoms in patients with chronic heart failure.

Nebivolol may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Headache: mild to moderate pain in the head. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: unusual tiredness or lack of energy. - Bradycardia: slower than normal heart rate. - Nausea: feeling of stomach upset. - Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure. - Heart block: impairment of electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in asthmatic patients. - Allergic reactions: rash, itching, or swelling of the face and throat. - Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, clinicians should consider several safety aspects.

- Monitor blood pressure: ensure adequate control and avoid excessive lowering. - Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. - Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may exacerbate bronchospasm. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Adjust dose in renal or hepatic impairment: consider reduced dosing in severe dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Combined with other β‑blockers: may cause excessive bradycardia or hypotension. - Co‑administration with non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): increases risk of heart block. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - ACE inhibitors or ARBs: additive blood pressure lowering, watch for hypotension. - Anti‑arrhythmic agents (e.g., amiodarone): may affect cardiac conduction.